Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab (KHK4827) in Systemic Sclerosis
NCT04368403Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brodalumab in systemic sclerosis (SSc), sponsored by Kyowa Kirin. Primary endpoint: Serum KHK4827 concentration. Started Oct 2017; status: completed.
02
Drugs
brodalumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04368403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368403.